SCHEMBL13952764

SCHEMBL13952764

C#Cc1ccc(OC)cc1N=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APOBEC3A P31941 1/20 0.36
▸ APOBEC3G Q9HC16 1/20 0.36
▸ MAPT P10636 4/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ CA12 O43570 2/20 0.35
▸ CA1 P00915 2/20 0.35
▸ CA2 P00918 2/20 0.35
▸ CA7 P43166 2/20 0.35
▸ CA9 Q16790 2/20 0.35
▸ CA14 Q9ULX7 2/20 0.35
▸ CYP1B1 Q16678 1/20 0.35
▸ CYP1A2 P05177 2/20 0.34
▸ CYP2A6 P11509 1/20 0.34
▸ RAB9A P51151 4/20 0.34
▸ NPC1 O15118 3/20 0.34
▸ ALDH1A1 P00352 4/20 0.33
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ HPGD P15428 3/20 0.33
▸ CYP3A4 P08684 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13078047 0.82 KDM4E (0.46) MAPTRAB9ANPC1ALDH1A1MEN1
SCHEMBL4433337 0.78 NPC1 (0.38) MAPTSMN1; SMN2CA12CA1CA2
SCHEMBL11933957 0.77 CYP1B1 (0.44) APOBEC3AAPOBEC3GMAPTSMN1; SMN2CA12
SCHEMBL30892213 0.73 CA12 (0.56) APOBEC3GMAPTSMN1; SMN2CA12CA1
SCHEMBL12463621 0.73 CA12 (0.56) APOBEC3GMAPTSMN1; SMN2CA12CA1
SCHEMBL12878065 0.73 MPI (0.46) APOBEC3AAPOBEC3GMAPTSMN1; SMN2CA12
SCHEMBL29007575 0.73 CA12 (0.40) MAPTSMN1; SMN2CA12CA1CA2
SCHEMBL987451 0.73 GAA (0.41) MAPTCA12CA1CA2CA7
SCHEMBL3434561 0.73 CA12 (0.56) MAPTCA12CA1CA2CA7
SCHEMBL13952761 0.72 TUBB4A (0.39) MAPTSMN1; SMN2CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042820-A1 Tubulin Binding Anti Cancer Agents And Prodrugs Thereof THRESHOLD PHARMACEUTICALS, INC. (US) 2009-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042820-A1 Tubulin Binding Anti Cancer Agents And Prodrugs Thereof TUBB1, TUBB, TUBB6 APOBEC3A 4605/4885APOBEC3G 4673/4885MAPT 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback